Determinants of survival following HIV-1 seroconversion after the introduction of HAART
Top Cited Papers
- 18 October 2003
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 362 (9392), 1267-1274
- https://doi.org/10.1016/s0140-6736(03)14570-9
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapyAIDS, 2001
- Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADEHIV Medicine, 2000
- Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE*AIDS, 2000
- Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysisThe Lancet, 2000
- Marked Declines in Human Immunodeficiency Virus–Related Mortality in Chicago in Women, African Americans, Hispanics, Young Adults, and Injection Drug Users, From 1995 Through 1997Archives of Internal Medicine, 2000
- A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and SurvivalJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998AIDS, 1999
- Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection DurationJAMA, 1998
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998